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Abstract
Background: The relationship between Helicobacter pylori infection and pancreatic cancer has
been investigated in three previous studies with contradictory results. The aim of the present study
was to investigate the association between H. pylori seropositivity and the risk for pancreatic cancer
in a nested case-control study within a population based cohort.
Methods: Selected birth-year cohorts (born 1921–1949) of residents in Malmö, Sweden, were
invited to a health screening investigation. A total of 33 346 subjects participated. Cases with
pancreatic cancer (n = 87) were matched to controls (n = 263) using age, sex and time for baseline
investigation as matching variables. H. pylori serology was analysed in stored serum samples using
an enzyme-linked immunosorbent assay. Odds ratios (OR) for pancreatic cancer were calculated
with 95% confidence intervals (CI) using logistic regression.
Results: H. pylori seropositivity was not associated with pancreatic cancer in the total cohort
(adjusted OR 1.25 (0.75–2.09)). However, a statistically significant association was found in never
smokers (OR 3.81 (1.06–13.63) adjusted for alcohol consumption) and a borderline statistically
significant association was found in subjects with low alcohol consumption (OR 2.13 (0.97–4.69)
adjusted for smoking).
Conclusion:  We conclude that no association between H. pylori infection and the risk for
pancreatic cancer was found in the total cohort. However, in never smokers and in subjects with
low risk alcohol consumption, a positive H. pylori serology was associated with an increased risk for
pancreatic cancer. These findings should be interpreted cautiously due to the limited number of
cases in these subgroups.
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Background
Pancreatic cancer is a relatively infrequent form of cancer
but due to the poor prognosis associated with the disease,
it ranks eight among the leading causes of cancer related
deaths worldwide [1]. Smoking is the most well docu-
mented risk factors for pancreatic cancer, estimated to
account for about 25% of all cases [2]. Alcohol consump-
tion is not an established risk factor for pancreatic cancer,
but there is a well known association between alcohol
consumption and chronic pancreatitis, and chronic pan-
creatitis is associated with an increased risk for pancreatic
cancer [3].
Helicobacter pylori infection has previously been associated
with gastric cancer [4-7] and mucosa-associated lymphoid
tissue lymphoma [8,9]. The association between H. pylori
infection and pancreatic cancer has been investigated in
three previous studies. One case-control study and one
prospective cohort study among smoking men have both
indicated an about doubled risk for pancreatic cancer in
H. pylori infected individuals [10,11]. However, this asso-
ciation could not be confirmed in a recent nested case-
control study performed in a cohort of subscribers to a
medical care program in the US [12].
The Malmö Preventive Project was set up in 1974 with the
main purpose to screen the middle-aged population for
cardiovascular disease risk factors [13]. The cohort con-
sists of 33 346 individuals subjected to a health screening
investigation sometime between 1974 and 1992 includ-
ing physical examination and a self-administered ques-
tionnaire. Stored blood samples are available from the
baseline investigation.
The objective of the present study was to investigate the
association between H. pylori infection and the risk of
pancreatic adenocarcinoma in relation to smoking and
drinking habits in this population based cohort.
Methods
The Malmö Preventive Project Cohort
In 1974, a Department of Preventive Medicine was set up
within The Department of Medicine at Malmö University
Hospital [13]. The main goal was to screen the middle-
aged population for risk factors for cardiovascular dis-
eases, diabetes mellitus and alcoholism. Complete birth-
year cohorts of registered residents in Malmö, Sweden,
were invited by letter to a health screening investigation
from 1974 to 1992. All men born in 1921, 1926–1942,
1944, 1946 and in 1948–49, and all women born in
1926, 1928, 1930–1938, 1941 and in 1949, were
included. The attendance rate was high (71%), and when
the recruitment ended a total of 33 346 individuals (22
444 men and 10 902 women) had participated. At base-
line examination subjects responded to a self-adminis-
tered questionnaire, weight and height were measured
and blood samples were collected. Selected biochemical
analyses were performed at baseline and the remaining
biological material was stored in a biological specimen
bank at -20°C.
Baseline exposure assessment
Weight and height were measured at baseline investiga-
tion by a trained nurse. Body mass index (BMI) was calcu-
lated as weight (kg) divided by length (m)2. Smoking
habits were assessed by questionnaire at baseline investi-
gation. The question "Have you ever been smoking on a
daily basis for at least six months?" was used to separate
those who had ever smoked ("ever smokers") from those
who had never smoked ("never smokers"). Ever smokers
were classified as current smokers if they had confirmed
current smoking, the remaining were classified as former
smokers. This procedure has been described in detail pre-
viously [14]. Alcohol consumption was estimated using a
scoring system that has been described in a previous pub-
lication[14] based on a modified version of the Michigan
Alcoholism Screening Test [15], the "Malmö modification
of the brief MAST" (Mm-MAST)[16]. In brief, subjects
answered 7 yes or no questions regarding drinking habits,
these answers were integrated into a scoring system which
was used to classify alcohol consumption as "low" "inter-
mediate" or "high" risk consumption [14]. No attempts to
quantify alcohol consumption were made. Gamma
glutamyl transferase (γ-GT) was measured at the time for
baseline investigation using γ-glutamyl-p-nitroanilin as a
substrate [17]. Values of γ-GT were available for all but 2
subjects. γ-GT values were used as an alternative marker
for alcohol consumption. The cohort was divided into ter-
tiles of γ-GT values, cut-off levels for the different tertiles
were identified in cases in order to construct three groups
of individuals with an equal number of cases in each
group.
Identification of cases and matching of control subjects
Cases of pancreatic cancer were identified by record link-
age of the Malmö Preventive Project cohort database to
the Swedish Cancer Registry using the ICD 7 diagnostic
code for pancreatic cancer (157). Cases that occurred until
31 December 1999 were included in the study. The record
linkage yielded 117 subjects registered with the diagnosis
of pancreatic cancer in the Malmö Preventive Project.
Clinical and pathology records were reviewed in all sub-
jects. The diagnosis of pancreatic adenocarcinoma could
be verified in 113 cases. Four cases were found to have
been erroneously registered as pancreatic adenocarcino-
mas (two islet cell tumors, one endocrine tumor and one
anaplastic malignancy) and were therefore excluded from
further analysis. All 113 cases were matched to 3 controls
resulting in a set of 452 subjects. Age was matched as +/-
180 days and time of baseline examination as +/- 180BMC Cancer 2008, 8:321 http://www.biomedcentral.com/1471-2407/8/321
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days. A large proportion of subjects examined during the
first year (Oct. 1974–1975) had no available biological
material. It was therefore decided that only subjects exam-
ined from 1 Jan. 1976 should be included in analyses,
resulting in a data set of 104 cases and 311 controls. Fol-
lowing sample retrieval and aliquoting, 87 cases had the
necessary amount of biological material. Considering the
relatively large number of subjects with missing biological
material, the matched analysis was abandoned at this
point. The laboratory analyses were, hence, performed in
87 risk sets ordered as 3 controls and 1 case. Following
analysis of another 3 controls, no more cases were availa-
ble and the laboratory analyses were finished. One ana-
lyzed control subject was excluded because of failure in
the H. pylori serology analysis. In all, 350 subjects were
included in the data analyses; 87 cases and 263 controls,
excluding 102 of the 452 subjects initially intended for
the study. Age, BMI and smoking habits were similar in
excluded and included subjects but there was a higher
proportion of men and a higher proportion of missing
information on alcohol consumption in the excluded
group. This difference was expected since mostly men
were investigated during the early phase of the study and
questions on alcohol were not introduced in the question-
naire until December 1976. Among included cases, evi-
dence for the diagnosis of pancreatic adenocarcinoma was
found in pancreatic resection specimens in nine cases, at
autopsy in 40 cases and by fine needle biopsy in 36 cases
(in 31 cases the biopsy was conclusive for pancreatic ade-
nocarcinoma and in 5 cases the biopsy showed low differ-
entiated adenocarcinoma of unclear origin but
radiological findings were indicative for a primary pancre-
atic tumor). In the remaining two cases the diagnosis was
based on the clinical picture and radiological findings
without any cytological or histopathological data.
H. pylori serology
IgG antibodies against H. pylori were measured by an in
house enzyme-linked immunosorbent assay (ELISA) at
the department of microbiology, Malmö University Hos-
pital, in blood samples from cases and controls stored at
baseline investigation [7]. Absorbance > 0.70 was
regarded as a positive test. The validity of this assay has
previously been investigated in a similar setting on stored
blood samples from the same cohort. Immunoreactivity
was found to be stable over time in that study. A bimodal
distribution in the absorbance level was demonstrated
with two distinct populations well separated by the cut-off
level of 0.70 [7].
Statistical analysis
All statistical calculations were performed using the soft-
ware SPSS 15.0. Median age, body mass index and time
from baseline investigation to analysis at baseline investi-
gation were calculated. The distribution of baseline char-
acteristics was compared between cases and controls and
between subjects with a positive and a negative H. pylori
serology. Unconditional logistic regression was used to
estimate crude and adjusted odds ratios (OR) with a 95%
confidence interval (CI). Conditional logistic regression
was considered inappropriate since the case-control
matching was disrupted due to the fact that blood samples
were missing for several cases and controls. Adjusted OR
were obtained by including age, sex, body mass index
(BMI), smoking, alcohol consumption according to the
Mm-MAST test, H. pylori serology and time from baseline
investigation to analysis, in the logistic regression model.
Simultaneous adjustment for Mm-MAST and γ-GT tertiles
was considered inappropriate since both are used as sur-
rogate markers for the same parameter, ie alcohol con-
sumption. Mm-MAST score was chosen as the principal
marker for alcohol abuse, since this variable was consid-
ered to be a more specific marker for alcohol abuse than
γ-GT. However, all calculations were repeated replacing
Mm-MAST category with γ-GT tertiles for comparison. OR
for pancreatic cancer in relation to H. pylori serology was
further studied in separate strata of smoking habits, Mm-
MAST category, γ-GT tertiles and BMI. Due to the small
number of cases in each stratum of smoking status or alco-
hol consumption, the number of covariates included had
to be reduced in these analyses. Possible covariates (age,
sex, body mass index (BMI), smoking, alcohol consump-
tion measured by Mm-MAST category, and time from
baseline investigation to analysis) were therefore included
one at a time in order to determine factors with a signifi-
cant impact on the association between H. pylori serology
and pancreatic cancer. As a comparison to the overall risk
calculations, OR adjusted for all covariates were calcu-
lated in order to allow assessment of the stability of the
statistical model, although the number of entered covari-
ates in this final analysis was formally unduly large.
Ethical Approval
The Ethical Committee at Lund University approved the
current study (LU 828-02; 6 Feb. 2003). In line with the
requirements of the local ethical committee, all partici-
pants in the Malmö Preventive Project were informed of
the present study by advertisements in local newspapers.
The possibility to withdraw from the current analysis was
explicitly stated.
Results
Baseline characteristics
Baseline characteristics for included cases and controls are
presented in table 1. Cases and controls were highly simi-
lar regarding matching factors despite the fact that the
case-control matching was partially disrupted (due to
missing blood samples as stated above). There was a
higher proportion of current smokers among cases. Alco-
hol consumption, as measured by the Mm-MAST test, wasBMC Cancer 2008, 8:321 http://www.biomedcentral.com/1471-2407/8/321
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similar in cases and controls. The median age for diagno-
sis among cases was 60.7 years (range 47.6–76.5). Base-
line characteristics by H. pylori serology are presented in
table 2. There was a slightly higher proportion of current
smokers among H. pylori positive subjects. Groups were
highly similar with regards to age, sex distribution and
time from baseline investigation to analysis of H. pylori
serology.
Association between H. pylori serology and pancreatic 
cancer in the total cohort
The risk for pancreatic cancer in different categories of H.
pylori serology, smoking habits and alcohol consumption
are presented in table 3 as crude OR and OR adjusted for
age, sex, BMI, H. pylori serology, smoking status, Mm-
MAST category and time from baseline investigation to
analysis. There was no association between H. pylori sero-
positivity and pancreatic cancer in the overall analysis
(adjusted OR = 1.25 (0.75–2.09)). Current smoking was
associated with a statistically significantly increased OR
for pancreatic cancer (adjusted OR = 3.59 (1.79–7.21)),
and there was a borderline significant increase in the OR
for pancreatic cancer among former smokers (adjusted
OR = 2.16 (0.97–4.82)). A tendency towards increased
OR's for pancreatic cancer in subjects with intermediate
and high risk alcohol consumption was observed but the
association was not statistically significant in any of these
groups (adjusted OR = 1.33 (0.77–2.32) and 1.84 (0.65–
5.23), respectively).
Stratified analyses of the association between H. Pylori 
and pancreatic cancer
The material was then stratified for smoking habits and
alcohol consumption in order to study the association
between a positive H. pylori serology and pancreatic cancer
in subgroups defined by these risk factors (table 4). The
size of the resulting subgroups was small and possible
covariates were therefore entered one at a time. BMI and
Table 1: Baseline characteristics of case with pancreatic cancer and control subjects
Factor Cases (n = 87) Controls (n = 263) p-value
Age (years) 47.9
(37.7–60.6)
47.5
(37.3–60.6)
0.53*
Sex Male 58
(66.7%)
187
(71.1%)
Female 29
(33.3%)
76
(28.9%)
Time from baseline investigation to analysis (years) 24.8
(14.3–28.8)
25.1
(18.1–29.0)
0.14*
Body mass index (kg/m2) 23.8
(18.0–41.0)
24.2
(17.6–34.2)
0.82*
Smoking status Never smoker 13
(14.9%)
88
(33.5%)
0.002**
Current smoker 55
(63.2%)
115
(43.7%)
Former 19
(21.8%)
60
(22.8%)
Mm-MAST category† Low 35
(40.2%)
129
(49.0%)
0.48**
Intermediate 42
(48.3%)
113
(43.0%)
High 7
(8.0%)
14
(5.3%)
Missing 3
(3.4%)
7
(2.7%)
γ-glutamyle transferase-tertiles (μkat/l) 1 (< 0.35) 31
(35.6%)
98
(37.5%)
0.63**
2 (0.35–0.60) 27
(31.0%)
90
(34.5%)
3(> 0.60) 29
(33.3%)
73
(28.0%)
Helicobacter pyori serology Negative 48
(55.2%)
163
(62.0%)
0.26**
Positive 39
(44.8%)
100
(38.0%)
Numbers represent n with column percent in brackets except for numbers in italics which represent medians with range in brackets.
*Mann-Whitney U-test ** Chi-square test.
†Mm-MAST, Malmö modification of the brief Michigan Alcoholism Screening Test.BMC Cancer 2008, 8:321 http://www.biomedcentral.com/1471-2407/8/321
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alcohol consumption measured by the Mm-MAST test
were the two cofactors that had the most important
impact on the association between positive H. pylori serol-
ogy and pancreatic cancer in never smokers. The OR for
pancreatic cancer related to positive H. pylori serology was
4.45 (1.19–16.69) when both these cofactors were
entered in the analysis (not shown in table). H. pylori sero-
positivity was associated with the risk for pancreatic can-
cer in subjects with a low risk alcohol consumption in the
unadjusted model (2.33 (1.09–4.97)). This association
remained statistically significant when adjusting for all
entered covariates, except for smoking status which
resulted in a borderline significant result (2.13 (0.97–
4.69)). In the small subgroup of subjects who reported a
low risk alcohol consumption and were never smokers (8
cases and 55 controls), the crude OR for pancreatic cancer
related to a positive H. pylori serology was 13.20 (2.31–
75.31) (not shown in table).
As a complement to the Mm-MAST test, γ-GT-values were
used to provide an alternative marker for alcohol con-
sumption. In subjects with a γ-GT value in the lowest ter-
tile, the crude OR for pancreatic cancer for subjects with a
positive compared to a negative H. pylori serology was
1.72 (0.75–3.96), in the middle γ-GT tertile it was 1.54
(0.65–3.66) and in the upper γ-GT tertile it was 0.90
(0.38–2.16) (not shown in table). In subjects who were
both never smokers and presented at baseline investiga-
tion with γ-GT values in the lowest tertile, the crude OR
for pancreatic cancer was 3.78 (0.79–18.13) for H. pylori
positive vs. H. pylori negative subjects (not shown in
table). Stratifying for BMI categories did not reveal any
statistically significant association between H. pylori posi-
tive subjects and pancreatic cancer in any BMI category
(data not shown).
Discussion
The association between pre-diagnostic measurements of
H. pylori serology and pancreatic cancer was investigated
in this population-based cohort study including both
men and women. H. pylori seropositivity was not associ-
ated with an increased risk for pancreatic cancer in the
Table 2: Baseline characteristics by Helicobacter pylori serology
H. pylori serology
Factor Category Negative Positive p-value
Age (years) 47.6
(37.3–60.6)
47.4
(37.7–60.6)
0.53*
Sex Male 144
(68.2%)
101
(72.7%)
0.38**
Female 67
(31.8%)
38
(27.3%)
Time from baseline investigation to analysis (years) 25.1
(14.3–28.9)
24.8
(14.3–29.0)
0.14*
Body mass index (kg/m2) 24.0
(17.6–37.8)
24.2
(18.2–41.0)
0.82*
Smoking status Never smoker 69
(32.7%)
32
(23.0%)
0.14**
Current smoker 96
(45.5%)
74
(53.2%)
Former 46
(21.8%)
33
(23.7%)
Mm-MAST category† Low 97
(46.0%)
67
(48.2%)
0.81**
Intermediate 97
(46.0%)
58
(41.7%)
High 12
(5.7%)
9
(6.5%)
Missing 5
(2.4%)
5
(3.6%)
γ-glutamyle transferase-tertiles (μkat/l) 1 (< 0.35) 87
(41.2%)
42
(30.7%)
0.14**
2 (0.35–0.60) 66
(31.3%)
51
(37.2%)
3(> 0.60) 58
(27.5%)
44
(32.1%)
Numbers represent n with column percent in bracket except for numbers in italics which represent medians with range in brackets.
*Mann-Whitney U-test ** Chi-square test.
†Mm-MAST, Malmö modification of the brief Michigan Alcoholism Screening Test.BMC Cancer 2008, 8:321 http://www.biomedcentral.com/1471-2407/8/321
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overall analysis. However, in never smokers, there was a
statistically significant association between H. pylori and
pancreatic cancer, and in subjects with low alcohol con-
sumption there were also indications for such an associa-
tion, although not statistically significant.
The validity of data collected at baseline investigation
invites discussion. A previous study in the Malmö Preven-
tive Medicine cohort has determined cut-off level of the
ELISA and demonstrated that the immunoreactivity in the
stored samples is stable despite the long storage time [7].
The prevalence of H. pylori seropositivity increases with
age [18]. This is thought to be a birth cohort effect, ie the
higher prevalence of seropositivity among elderly people
reflects a higher childhood infection rate at the time when
they were children rather than acquisition during adult
life [19,20]. It is therefore reasonable to assume that most
subjects with a negative H. pylori serology at baseline
investigation probably remained uninfected until end of
follow-up. Since controls were matched both for age and
Table 3: Crude and adjusted odds ratios (OR) for pancreatic cancer with 95% confidence intervals (CI) by Helicobacter pylori serology, 
smoking status and alcohol consumption
Factor Status Crude OR (95% CI) OR (95% CI)*
H. pylori serology Negative 1.00 (reference) 1.00 (reference)
Positive 1.32 (0.81–2.16) 1.25 (0.75–2.09)
Smoking Never smoker 1.00 (reference) 1.00 (reference)
Current smoker 3.24 (1.67–6.30) 3.59 (1.79–7.21)
Former smoker 2.14 (0.99–4.67) 2.16 (0.97–4.82)
Mm-MAST** category Low 1.00 (reference) 1.00 (reference)
Intermediate 1.37 (0.82–2.29) 1.33 (0.77–2.32)
High 1.84 (0.69–4.92) 1.84 (0.65–5.23)
Missing 1.58 (0.39–6.43) 1.86 (0.42–8.15)
γ-glutamyle transferase-tertiles (μkat/l) 1 (< 0.35) 1.00 (reference) 1.00 (reference)
2 (0.35–0.60) 0.95 (0.53–1.71) 0.83 (0.44–1.59)
3 (> 0.60) 1.27 (0.70–2.27) 1.07 (0.54–2.12)
* Odds ratios for the risk factors H. pylori serology, smoking and Mm-MAST category are adjusted for age, sex, body mass index, H. pylori serology 
status, smoking status, time from baseline investigation to analysis and alcohol consumption. Mm-MAST is used as surrogate marker for alcohol 
consumption, no adjustment is done for γ-glutamyle transferase values. Adjusted OR for γ-glutamyle transferase-tertiles are adjusted for the same 
cofactors except for Mm-MAST category.
** Mm-MAST, Malmö modification of the brief Michigan Alcoholism Screening Test.
Table 4: Odds ratios for pancreatic cancer with 95% confidence intervals by Helicobacter pylori serology stratified for smoking status 
and alcohol consumption (no reference categories shown in table)
Factors Smoking status Alcohol consumption **
Never smoker Current smoker Former smoker Low risk Intermediate risk High risk
Cont Case* Cont Case* Cont Case* Cont Case* Cont Case* Cont Case*
H. pylori positive (n) 25 7 50 24 25 8 47 20 41 17 7 2
H. pylori negative (n) 63 6 65 31 35 11 82 15 72 25 7 5
H. pylori (crude) 2.94 (0.90–9.61) 1.01 (0.53–1.92) 1.02 (0.36–2.90) 2.33 (1.09–4.97) 1.19 (0.58–2.47) 0.40 (0.057–2.80)
H. pylori + age 2.95 (0.89–9.81) 1.01 (0.53–1.92) 1.01 (0.35–2.87) 2.31 (1.08–4.97) 1.20 (0.58–2.48) 0.42 (0.058–3.04)
H. pylori + sex 3.04 (0.91–10.18) 1.01 (0.53–1.93) 0.99 (0.35–2.86) 2.33 (1.09–4.98) 1.23 (0.59–2.55) 0.34 (0.048–2.46)
H. pylori + time to analysis 3.40 (0.99–11.72) 1.00 (0.52–1.91) 1.07 (0.37–3.08) 2.32 (1.08–4.96) 1.25 (0.60–2.61) 0.37 (0.052–2.69)
H. pylori + BMI*** 3.77 (1.05–13.48) 1.00 (0.52–1.92) 1.20 (0.41–3.53) 2.33 (1.09–4.97) 1.19 (0.57–2.46) 0.30 (0.035–2.61)
H. pylori + alcohol** 3.81 (1.06–13.63) 1.03 (0.53–1.99) 1.19 (0.39–3.61) - - -
H. pylori + smoking status - - - 2.13 (0.97–4.69) 1.29 (0.61–2.73) 0.29 (0.035–2.40)
H. pylori + all covariates 4.97 (1.23–20.10) 1.01 (0.52–1.97) 1.52 (0.45–5.10) 2.19 (0.98–4.88) 1.38 (0.64–2.98) 0.24 (0.023–2.48)
*Controls/Cases
**Alcohol consumption estimated by the Malmö modification of the Michigan Alcoholism Screening Test. OR in subjects with missing alcohol 
consumption data are not reported due to small number of controls (n = 7) and cases (n = 3).
***BMI, body mass indexBMC Cancer 2008, 8:321 http://www.biomedcentral.com/1471-2407/8/321
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time of baseline investigation we do not believe that the
changing H. pylori prevalence over time and age in this
population has introduced any major bias of the results. It
is possible that some of the H. pylori positive subjects have
been eradicated after baseline investigation which may
have attenuated a potential association between H. pylori
infection and pancreatic cancer to some extent. However,
since the baseline investigation in this study was per-
formed in middle aged subjects, it is reasonable to assume
that even an individual that was eradicated after the
screening visit would have had a fairly long life-time expo-
sure for H. pylori infection. Alcohol consumption was esti-
mated by two separate means, the Mm-MAST test and γ-
GT levels in serum. The Mm-MAST test is a validated ques-
tionnaire for detection of high risk alcohol consumption.
The questionnaire is directed towards drinking behavior
but does not contain questions on amounts of ingested
alcohol [16]. It has been argued that leaving out this type
of quantifying question would make the test a more valid
tool for detecting individuals with a high risk alcohol con-
sumption [16]. The validity of γ-GT as a tool for detection
high alcohol consumption has been investigated in
numerous previous studies. In the primary health care set-
ting, the reported sensitivity is 20–40% and the specificity
around 90% in most studies [21]. Using γ-GT instead of
the Mm-MAST test to adjust for alcohol consumption in
the logistic regression model gave similar results. The
validity of self-reported data on smoking habits has been
investigated previously in this cohort. A high agreement
between plasma levels of carboxyhaemoglobin and self-
reported smoking status was reported indicating that the
risk for misclassification bias in this regard is probably
low [22].
The ascertainment of cases is another potential source of
misclassification bias. The Swedish Cancer registry has
previously been reported to be 98% complete, indicating
a low risk for missed cases [23]. In this study, all case files
and pathology reports were reviewed in order to validate
the diagnosis of pancreatic adenocarcinoma. The median
age at diagnosis in our study was 60.7 years which is
slightly lower than the median of 65 years that is usually
reported for pancreatic cancer [2]. This can be explained
by the fact that the majority of the cohort has not yet been
followed to a very high age. Consequently, the results
might not be applicable to pancreatic cancer occurring at
higher ages. It is possible that participants and non-partic-
ipants in the Malmö Preventive Project differed regarding
the distribution of risk factors or the type of pancreatic
cancer. However, the high attendance rate (71%) and the
population-based recruitment are considerable strengths
in this study that have probably limited a potential selec-
tion bias.
The present study included 87 cases which makes it
slightly smaller than the previously published studies
from Finland and the US [11,12]. Hence, it is possible that
the lack of a statistically significant association between
H. pylori serology and pancreatic cancer in the overall
analysis and among current smokers is due to a type II
error. That is, we may have missed a true difference due to
poor statistical power. However, it is probable that such a
potential association is not very strong, considering that
the estimated OR with 95% CI for pancreatic cancer
among H. pylori positive subjects was 1.25 (0.75–2.09) in
the total cohort and 1.01 (0.53–1.92) among current
smokers in this study. Furthermore, our results are in
accordance with the US study [12].
The association between H. pylori seropositivity and pan-
creatic cancer in both never smokers and low risk consum-
ers of alcohol is a potentially important observation but
being a subanalysis it has to be interpreted cautiously.
These subgroups were small and, as a consequence, it was
difficult to adjust for all potential confounders on the
same time in the statistical model. However, the inclusion
of these variables one at a time did not influence the
results to any major extent, and we consider that con-
founding due to these factors can only have been a minor
problem.
The association between H. pylori and pancreatic cancer
has been investigated in three previous studies. A case
control study was performed in Austria by Raderer et al on
92 patients with pancreatic cancer that were compared to
a control group consisting of 35 patients with colorectal
cancer and 27 healthy volunteers [10]. H. pylori seroposi-
tivity was associated with an OR of 2.1 (1.1–4.1) for pan-
creatic cancer in that study. A nested case-control study on
the association between H. pylori serology and pancreatic
cancer in a Finnish cohort was performed by Stolzenberg-
Solomon et al [11]. In that study the OR for pancreatic
cancer was 1.87 (1.05–3.34) adjusted for total time of
smoking. Recently, a nested case-control study on the
association between H. pylori and pancreatic cancer within
a US cohort of subscribers to the Kaiser Permanente Med-
ical Care Program, including 104 cases and 262 controls,
was published [12]. In contrast to the previous two stud-
ies, no association between H. pylori infection and pancre-
atic cancer was observed. Subgroup analysis did not reveal
any association in smoking men. The association between
H. pylori serology and pancreatic cancer among never
smokers was not reported. The relatively large sample size
and the nested case-control design with analysis of H.
pylori serology on prospectively collected blood samples
are strengths in the latter two studies. However, it may be
difficult to compare our results to the Finnish study since
it only included smoking middle-aged men. Our findings
are in accordance with the US study that was performed in
a more heterogeneous cohort including both men and
women regardless of smoking habits. A strong point in
our study is that it is performed in a population basedBMC Cancer 2008, 8:321 http://www.biomedcentral.com/1471-2407/8/321
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cohort, facilitating generalization of the results to other
populations.
Pancreatic secretion is under hormonal control mainly by
cholecystokinin which stimulates enzyme production and
secretion from acinar cells and by secretin which induces
bicarbonate secretion from ductal cells [24]. Secretin is
released by cells in the duodenal wall in response to a
local fall in pH that occurs when foods mixed with gastric
acid enters the duodenum [25]. Several mechanisms have
been proposed for the potential association between H.
pylori infection and pancreatic cancer. Antral colonization
by H. pylori has been associated with increased gastric acid
output which will lead to increased secretin release from
the duodenum. Secretin stimulation has been proven to
accelerate the development and frequency of pancreatic
tumors induced by nitrosamines in a hamster model [26].
One possible hypothesis is that the increased secretin lev-
els associated with antral H. pylori infection, either per se
or by acting as a cocarcinogen, increase the risk of pancre-
atic cancer [27]. Opposite to antral colonalization, H.
pylori infection of the corpus area of the stomach is associ-
ated with a loss of parietal cells and a decrease in gastric
acid out-put [27]. A second mechanism for an association
between H. pylori infection and pancreatic cancer has been
proposed derived from this model. Hypoacidity can lead
to bacterial overgrowth and increased production of N-
nitroso compounds which can be activated in the ductal
epithelium after transportation to the pancreas by the cir-
culation. This second hypothesis related to hypoacidity is
supported by the observation that pernicious anemia is
associated with pancreatic cancer [28,29]. An increased
risk for pancreatic cancer was demonstrated in patients
with gastric, but not duodenal ulcers in a recently pub-
lished register based Swedish study by Luo et al [30]. This
observation suggests that if there is an association
between  H. pylori and pancreatic cancer, the second
hypothesis with decreased acid out-put due to H. pylori
infection of the gastric mucosa is the probable mechanism
since gastric, but not duodenal, ulcers are associated with
this form of infection.
The possibility of intrapancreatic invasion by Helicobacter
species has been investigated in resections specimens
from pancreatic cancer, chronic pancreatitis and normal
pancreatic tissue [31]. In that study Helicobacter  DNA
could be detected in 30 out of 40 patients with pancreatic
cancer, and in 3 out of 5 patients with chronic pancreati-
tis. All 7 samples from normal pancreas were Helicobacter
negative. Increased secretion of vascular endothelial
growth factor and interleukin 8 has been observed in vitro
after incubation of pancreatic cancer cell-lines with H
pylori, providing a possible way for how H pylori could
increase the malignant potential if intrapancreatic infec-
tion occurred [32]. The relevance of these findings
remains to be elucidated.
Gastric acid secretion has been demonstrated to be influ-
enced by smoking [33-35] and consumption of non-dis-
tilled alcoholic beverages produced by fermentation has
been proven to increase gastric acid out-put and gastrin
release [36]. Moreover, smoking is an important source of
n-nitroso compound exposure in humans [37], and
increased concentrations of tobacco-specific nitrosamines
has been demonstrated in the pancreatic juice of smokers
[38]. In the present study, there was an association
between  H. pylori seropositivity and pancreatic cancer
only in never smokers and in subjects with low risk alco-
hol consumption. A possible explanation to this is obser-
vation could be that the effect of a weak risk factor such as
H. pylori infection is more important in the absence of
stronger risk factors such as smoking and alcohol con-
sumption since all three possible risk factors have been
suggested to influence the risk for pancreatic cancer
through the same mechanisms, i.e. gastric acid secretion
and production of n-nitroso compounds.
Conclusion
In summary, we did not find any statistically significantly
increased risk for pancreatic cancer among subjects with a
positive H. pylori serology in the overall analysis in this
nested case-control study. We cannot completely exclude
that the lack of an association between H. Pylori seropos-
itivity and pancreatic cancer in our study was due to insuf-
ficient statistical power but our results indicate that H.
pylori infection is probably not a strong risk factor for pan-
creatic cancer in the general population. However, a posi-
tive H. pylori serology was associated with an increased
risk for pancreatic cancer in subgroups of subjects classi-
fied as never smokers or low risk consumers of alcohol.
These observations should be interpreted cautiously, bear-
ing in mind the limited number of cases in these sub-
groups.
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